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Abstract: COVID-19 is a novel disease caused by SARS-CoV-2 which has conquered the world rapidly
resulting in a pandemic that massively impacts our health, social activities, and economy. It is likely
that vaccination is the only way to form “herd immunity” and restore the world to normal. Here
we developed a vaccine candidate for COVID-19 based on the virus-like particle AP205 displaying
the spike receptor binding motif (RBM), which is the major target of neutralizing antibodies in
convalescent patients. To this end, we genetically fused the RBM domain of SARS-CoV-2 to the C
terminus of AP205 of dimerized capsid proteins. The fused VLPs were expressed in E. coli, which
resulted in insoluble aggregates. These aggregates were denatured in 8 M urea followed by refolding,
which reconstituted VLP formation as confirmed by electron microscopy analysis. Importantly,
immunized mice were able to generate high levels of IgG antibodies recognizing eukaryotically
expressed receptor binding domain (RBD) as well as spike protein of SARS-CoV-2. Furthermore,
induced antibodies were able to neutralize SARS-CoV-2/ABS/NL20. Additionally, this vaccine
candidate has the potential to be produced at large scale for immunization programs.
Keywords: virus-like particles; AP205-VLPs; RB motif; humoral immune response
1. Introduction
The current global pandemic of COVID-19 caused by the new coronavirus SARS-
CoV-2 has a large impact on the economic and social life worldwide. To date, about 120
million people have been infected, with approximately 2.5 million deaths (source:WHO).
Similar to the disease caused by the other two viruses SARS (SARS-CoV) and MERS (MERS-
CoV), COVID-19 leads to systemic infection and may cause organ failure, particularly of
the lung [1]. In contrast to SARS-CoV and MERS-CoV, which could be contained more
efficiently, SARS-CoV-2 spreads more rapidly because of infected asymptomatic individuals
(mostly pre-symptomatic) who can transmit the virus [2]. To limit the damage of COVID-19,
primary efforts focus on confinement, with physical distancing and multiple further non-
pharmaceutical measures to prevent infection [3,4]. At present, many investigations aim
at defining optimal strategies to limit viral transmission while simultaneously permitting
business and social life activities [5]. One of these strategies is to rapidly increase the
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human immunity using vaccines against COVID-19. Different vaccines based on RNA
and adenoviral vectors have been developed and several of them have already been
approved for emergency use in many countries. Other traditional vaccine platforms such
as those based on recombinant proteins or subunit vaccines are still in clinical or preclinical
development [6]. Despite the achievement of marketed vaccines, there is still a strong need
for more doses as re-vaccinating people into 2022 may be required as well as having a
platform for future emerging coronaviruses. Therefore, investing in the development of
safe, effective, and affordable coronavirus vaccines continues to be of high priority.
The neutralizing antibodies against SARS-CoV-2 are mostly specific for the receptor
binding domain (RBD) of the spike protein. Within RBD, the receptor binding motif (RBM)
is considered the most important site which directly interacts with ACE2. As compared
to SARS-CoV, the affinity to ACE2 of the original spike of SARS-CoV-2 is about 4-fold
higher, offering an explanation for the increased infectivity of the latter. Consequently,
generating a vaccine inducing antibodies against spike or RBD is the preferred strategy
of the majority of COVID-19 vaccine candidates [7]. It has recently been shown that in
contrast to most parts of the spike protein, RBD shows minimal glycosylation as it only
contains two glycosylation sites, and the RBM is not glycosylated at all. Furthermore,
the two glycosylation sites of RBD are distant from the RBD-ACE2 interaction interphase
(RBM) and do not interfere with the spike-ACE2 receptor interaction [8]. This confirms
that the generation of vaccines inducing antibodies against RBD and especially against
RBM is a valuable strategy to fight the pandemic [7].
Virus-like particles (VLPs) represent one of the relatively traditional vaccine platforms
in the sense that they have already proven their clinical usefulness. VLPs consist of
viral structural proteins that upon recombinant expression, self-assemble into particles,
mostly icosahedrons and rarely helical [9]. We have previously described the favorable
characteristics of VLPs and the reason they constitute a good vaccine template and have
given rise to highly successful vaccines [10–12]. VLPs derived from Leviviridae have
gained considerable attention in the field of vaccinology as a versatile platform [13]. A
great interest has been directed against the capsid architecture of phage-VLPs such as MS2,
PP7, Qβ and recently AP205. Such knowledge is crucial to pinpoint the surface reactive
amino acids which are essential to chemically couple or insert foreign epitopes within the
coat protein (CP). AP205 phage infects Acinetobacter bacteria. AP205-VLPs forms stable
particles and have a robust coat protein that can accommodate large insertions into the C or
N termini [13]. The crystallographic asymmetric unit of an AP205-VLP contain a single CP
dimer which consists of chains A and B representing two monomers. The dimer structure
feature is special in as much as the C terminus of one monomer is in close proximity with
the N-terminus of the other monomer. In comparison to other phages such as MS2, the CP
of AP205 is missing a beta strand in its N-terminus and has an extra beta strand in the C
terminus. Accordingly, AP205 has N and C-termini in the same location and well-exposed
on the surface which explains the ability of AP205 to tolerate and accommodate long
insertions at either termini without compromising the capsid integrity [14].
In this study, we have shown that the bacteriophage AP205-VLPs can be used as an
effective platform for the development of a COVID-19 vaccine against SARS-CoV-2. This
system also facilitates large-scale production of the vaccine. The developed platform can
also be optimized to tackle the emerging variants of SARS-CoV-2, an area of research we
are currently exploring.
2. Materials and Methods
2.1. Mice
All in vivo experiments were performed using (8–12 weeks old) wild-type female
BALB/cOlaHsd mice purchased from Harlan. All animal procedures were conducted in
accordance with the Swiss Animal Act (455.109.1–5 September 2008) of University of Bern.
All animals were treated for experimentation according to protocols approved by the Swiss
Federal Veterinary Office.
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2.2. AP205-RBM Vaccine Cloning, Expression, and Production
To design and develop AP205-RBM vaccine, we first genetically fused two codon-
optimized synthesis AP205 monomers and subcloned them into the modified pETDuet-1
vector to construct the pETDuet-1-AP205 dimer plasmid. RBM gene encoding residues
437–508 of SARS-CoV-2 Spike protein (GenBank accession number QIA98606.1) was am-
plified by polymerase chain reaction (PCR )with Q5® High-Fidelity Master Mix (New
England Biolabs, Ipswich, MA, USA) using codon-optimized synthesis pUCIDT-SARS-
CoV-2-RBD plasmid gifted from Prof Andris Zeltins (Latvian Biomedical Research and
Study Center) as template and C-terminal fused with VLP AP205-dim between the Bmt
I and Hind III sites in the pETDuet-1-AP205 dimer plasmid from our laboratory and
a C-terminal 6xHis-tag. For amplification following primers were used for PCR: F: 5′-
tctgatactactgctagcggatccaacagcaacaacc-3′ and R: 5′-attatgcggccgcaagctttagtgatggtgatggt
gatgactagtatacggctgatag-3′. The corresponding PCR fragment was analyzed in 1.2%
agarose gel and then purified with GeneJet Gel Extraction kit (Thermo Scientific, Cars-
bad, CA, USA). The PCR product of 3′terminal end and plasmid pETDuet-1-AP205 were
digested with enzymes Bmt I and Hind III (Thermo Fischer Scientific, Waltham, MA, USA)
and ligated, resulting in plasmid pETDuet-1-AP205-RBM. E. coli XL1-Blue cells were used
as a host for cloning and plasmid amplification. After sequencing, the plasmid clones
without sequence errors were then subcloned into T7 Express Competent E. coli C2566
(High Efficiency) (New England Biolabs, Ipswich, MA, USA).
Expression and purification of AP205-RBM: E. coli cultures were grown in lysogeny
broth (LB) medium containing Ampicillin (100 µg/mL) on a rotary shaker (200 rev/min;
Infors, Bottmingen, Switzerland) at 37 ◦C to an OD600 of 0.4–0.8. Then, the expression
was induced with 0.1 mM Isopropyl-β-D-thiogalactopyranoside (IPTG). Incubation was
continued on the rotary shaker at 16 ◦C for 16 h. The resulting biomass was collected by
low-speed centrifugation and was frozen at −70 ◦C. After thawing on ice, the cells were
suspended in the buffer containing 20 mM Tris-HCl pH 8.0 supplemented with 100 mM
NaCl with additional 2 mM EDTA, 1 mM PMSF, 5% glycerol, and 0.1% Triton X-100
were disrupted by ultrasonic treatment. Insoluble and soluble proteins were separated by
centrifugation (14,000 rpm, 20 min at 4 ◦C). All steps involved in the expression of VLP
were monitored by SDS-PAGE using 12% gels.
2.3. Protein Refolding and Purifying
Cell pellets was resuspended in lysis buffer (10 mL buffer for 1 g cells), sonicated
and centrifuged for 20 min, 10,000× g at 4 ◦C. Discard supernatant, the pellets were
resuspended for individual wash steps: sonicate, centrifuge for 20 min, 10,000× g at 4 ◦C,
and repeated for 4×. After last time centrifuge, debris was resuspended in inclusion body
(IB) solubilization buffer (8 M urea, 20 mM Tris-HCl and 100 mM NaCl) and incubate for
16 h, 4 ◦C on rotating wheel (slow rotation). Following centrifuging for 20 min, 10,000× g
at 4 ◦C, IB supernatant was dialyzed against refolding buffer (RB) I buffer with 4 M urea,
20 mM Tris-HCl, 0.5 M Arginine, 5 mM reduced Glutathione and 0.5 mM L-oxidized
Glutathione for 24 h at 4 ◦C, subsequently RB II buffer (2 M urea, 20 mM Tris-HCl, 0.5 M
Arginine, 5 mM reduced Glutathione and 0.5 mM L-oxidized Glutathione) for 24 h at
4 ◦C. Finally, dialyzed in RB III buffer (20 mM Tris-HCl, 0.5 M Arginine, 5 mM reduced
Glutathione and 0.5 mM L-oxidized Glutathione) for 36 h at 4 ◦C. After centrifuge for
20 min, 10,000× g at 4 ◦C, VLP refolding fusion protein in supernatant was analyzed on
12% SDS-PAGE gel and was purified by HisTrap™ High Performance (GE Healthcare,
Freiburg, Germany).
2.4. Electron Microscopy
2 µL of purified AP205-RBM protein (1 mg/mL) suspension for negative staining were
adsorbed on glow discharged and carbon coated copper grids (Plano, Wetzlar, Germany) for
1 min at room temperature (RT). After 3× washing by pure water, grids were stained with
2% uranyl acetate solution (Electron Microscopy Science, Hatfield, MA, USA) for 30 s. The
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excess fluid was removed by gently pushing them sideways to filter paper. Samples were
then examined with a transmission electron microscope (Tecnai Spirit, FEI, Hillsboro, OR,
USA) at 80 kV and equipped with a digital camera (Veleta, Olympus, Münster, Germany).
2.5. Mass Spectrometry
AP205-RBM (1 mg/mL) were diluted with a 3-hydroxypicolinic acid matrix solution
and were spotted onto a modulated tool path (MTP) Anchor Chip 400/384TF. Matrix-
assisted laser desorption/ionization (MALDI)-TOF MS analysis was carried out on a
MALDI-MS (Thermo Scientific, San Jose, CA, USA).
2.6. Vaccination Regimen
Wild-type Balb/c female mice (8 weeks, Harlan) were vaccinated subcutaneously (s.c.)
with 100 µg AP205-RBM in 100 µL PBS or with AP205 VLPs control in 100 µL PBS on day
0. Mice were boosted with a similar dose on day 28. Serum samples were collected on days
14, 21, 35, and 49, respectively.
2.7. The Enzyme-Linked Immunosorbent Assay (ELISA)
For determination of total IgG antibodies titers against AP205-RBM in sera of immu-
nized mice, ELISA plates were coated with 0.1 µg/mL and 1.0 µg/mL spike RBD or full
spike proteins (Sinobiological, Beijing, China) overnight, respectively. Plates were washed
with PBS-0.01% Tween and blocked using 100 µL PBS-Casein 0.15% for 2 h in RT. Sera from
immunized mice were diluted 1/20 initially and a 1/3 dilution chain was performed. Plates
were incubated for 1 h at RT. After washing with PBS-0.01%Tween (PBST), goat anti-mouse
IgG conjugated to Horseradish Peroxidase (HRP) (Jackson ImmunoResearch, West Grove,
PA, USA) was added 1/2000 and incubated for 1 h at RT. Plates were developed and OD
450 reading was performed. Antibody titers were determined as the concentrations of
antibody at 50% maximum optical density (OD50). IgG subclasses were measured from day
35 sera using the same ELISA protocol with the following secondary Abs: goat anti-mouse
IgG1-HRP and goat anti-mouse IgG2a-HRP (1:1000) (Thermo Fischer Scientific, Waltham,
MA, USA), goat anti-mouse IgG2b-HRP (SouthernBiotech, Birmingham, AL, USA) 1:4000,
rat anti-mouse IgG3-HRP (Becton, Dickinson, Franklin Lakes, NJ, USA) 1:2000 incubated
at RT for 1 h.
2.8. Antibody Avidity Measurement
To test IgG antibody avidity against SARS-CoV-2 full spike protein and RBD protein,
serial three-fold dilution serum samples from immunized mice, 1/20 initially performed,
were added to ELISA plates coated over night with 1.0 µg/mL RBD and Spike proteins,
respectively. After incubation at RT for 1 h, the plates were washed once in PBS-0.01%
Tween, and then washed 3× with 7 M urea in PBS-0.05%Tween or with PBS-0.05% Tween
for 5 min every time. After washing with PBS-0.05%Tween, goat anti-mouse IgG conjugated
to Horseradish Peroxidase (HRP) (Jackson ImmunoResearch, West Grove, PA, USA) was
added 1/2000 and incubated for 1 h at RT. Plates were developed and read at OD 450 nm.
2.9. Neutralization Assay
Vesiculoviral pseudotyped virus production has been described elsewhere [14] with
the only change being the use of pCAGGS_SARS-CoV-2_Spike (a kind gift from Dr Emma
Bentley NIBSC). After establishing the TCID50 of the stock on HEK293T/17 cells transiently
expressing ACE2 and TMPRSS2 (pCAGGS ACE2 and TMPRSS2 both kind gifts from
Dr Nigel Temperton University of Kent), neutralization assays were undertaken using
100 × TCID50 per well of 96-well plate. The virus was incubated for 1 h at 37 ◦C (5%
CO2) along with the heat-inactivated serum, which was diluted over a range of 1:20–1:500,
after which 2 × 104 HEK293T/17 cells transiently expressing ACE2 and TMPRSS2 were
added to each well and the plate left to incubate (37 ◦C, 5% CO2) for a further 48 h. The
media was then discarded and the level of report gene activity assessed using a 50:50
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mix of non-supplemented media: BrightGlo and a read in a GloMax Discover (Promega,
London, UK).
CPE-based assay: the capacity of the induced antibodies in neutralizing wild-type
SARS-CoV-2 (SARS-CoV-2/ABS/NL20) was also performed. Serum samples were heat-
inactivated for 30 min at 56 ◦C. Two-fold serial dilutions were prepared starting at 1:20 up
to 1:160. 100 TCID50 of the virus was added to each well and incubated for 37 ◦C for 1 h.
The mixture has been added on a monolayer of Vero cells and incubated again for 37 ◦C for
4 days. Four days later the cells were inspected for cytopathic effect (CPE). The titer was
expressed as the highest dilution that fully inhibits formation of CPE.
2.10. Statistical Analysis
Data were analyzed and presented as mean ± SEM using GraphPad PRISM 8. Com-
parison between the groups was performed using Student’s t-test (non-parametric). The
p value was considered statistically significant if <0.05 (** p < 0.01; * p < 0.05).
3. Results
3.1. The Bacteriophage AP205-VLPs Can Be Used Efficiently for Generating a Fusion Vaccine
Against SARS-CoV-2
In our previous studies, we have provided a proof-of-concept that AP205-VLPs consti-
tute an efficient vaccine platform that is suitable for fusing epitopes of different lengths such
as peptides from angiotensin II, CXCR4 receptor, influenza A M2 protein or gonadotropin
releasing hormone (GnRH). These epitopes could efficiently be fused at the N or C terminus
of AP205 and allowed the assembly of VLPs without compromising their integrity [15].
Furthermore, a stabilized version of AP205 has recently been designed by fusing 2 capsid
proteins with a small linker, resulting in VLPs with 90 N and C termini. In the current study,
the RBM domain (aa437–508) of the spike of SARS-CoV-2 was added to the C terminus
of AP205 dimer as illustrated in Figure 1A. The construct was expressed in E. coli for
the possibility to scale up and allowed spontaneous packaging of ssRNA which serve as
toll-like receptor (TLR) 7/8 agonist. Expression resulted in large amounts of insoluble
aggregates which could, however, easily be denatured and refolded using urea (Figure 1B).
The production of AP205-RBM fusion protein was confirmed by SDS-PAGE showing a
band of ~37.4 kDa (Figure 1C) equivalent to AP205 dimers displaying 1 RBM domain. To
confirm the integrity of the produced vaccine we performed electron microscopy (EM) as
well as Mass Spectrometry (MS) analysis. The EM and MS confirmed the formation of
VLPs ~25–30 nm in size as shown in Figure 1D and E. The developed vaccine incorporates
~90 RBM corresponding to the number of dimers in AP205 (Figure 1F).
3.2. Vaccination with AP205-RBM Vaccine Induces High Titers of RBD and Spike-Specific
IgG Abs
To test the immunogenicity of the developed vaccine candidate, we performed in vivo
studies. BALB/c mice were primed s.c. with 100 µg of AP205-RBM on day 0 and received
a boost of 100 µg on day 28 (Figure 2A). Mice were bled weekly to measure the induced
antibodies against RBD and Spike proteins of SARS-CoV-2. AP205 VLPs were used as a
control. The results showed an increase in RBD (Figure 2B,C) and Spike (Figure 2D,E) spe-
cific antibody titers 14 days after priming which continued to increase steadily. Following
the booster injection on day 28, the titer increased by ~2-folds. No RBD-specific antibodies
were detected in the mice vaccinated with AP205 as a control.




Figure 1. The bacteriophage AP205-VLPs can be used efficiently for generating a fusion vaccine against SARS-CoV-2. (A) 
Schematic representation of AP205-RBM coat protein fusion construct. (B) 12% SDS-PAGE for AP205-RBM expression in 
E. coli showing soluble (S) and insoluble (P) fractions. (C) 12% SDS-PAGE showing the purified AP205-RBM vaccine of 
~37.4 kDa. (D) Electron Microscopy of negatively stained AP205-RBM VLPs showing a size of ~30 nm, scale bar 200 nm. 
(E) MALDI-MS of AP205-RBM vaccine. (F) 3D model of AP205-RBM vaccine illustrating AP205 CP in yellow and the 
genetically fused RBM in red. 
 
Figure 1. The bacteriophage AP205-VLPs can be used efficiently for generating a fusion vaccine against SARS-CoV-2. (A)
Schematic representation of AP205-RBM coat protein fusion construct. (B) 12% SDS-PAGE for AP205-RBM expression
in E. coli showing soluble (S) and insoluble (P) fractions. (C) 12% SDS-PAGE showing the purified AP205-RBM vaccine
of ~37.4 kDa. (D) Electron Microscopy of negatively stained AP205-RBM VLPs showing a size of ~30 nm, scale bar 200
nm. (E) MALDI-MS of AP205-RBM vaccine. (F) 3D model of AP205-RBM vaccine illustrating AP205 CP in yellow and the
genetically fused RBM in red.
3.3. AP205-RBM Vaccine Promotes IgA Production and IgG Responses Dominated by IgG2a
In a next step, we tested the ability of the vaccine to induce immunoglobulin class-
switching to IgA. To this end, ELISA plates were coated with RBD and mouse sera from
day 49 was used to measure induction of specific IgA. The obtained results demonstrate a
strong ability of the vaccine to induce RBD-specific IgA antibodies as shown in Figure 3A.
Measuring the OD50 of IgA response of AP205-RBM confirmed induction of strong IgA
responses (Figure 3B).
Mouse IgG antibodies are known to be heterogenous and basically consist of four
subclasses, for BALB/c mice: IgG1, IgG2a, IgG2b, and IgG3. The subclasses vary in
their immunological, biochemical as well as physiological properties. It has been shown
in previous studies that IgG2a and IgG2b play an essential role against pathogens by
enhancing opsonization, complement fixation and immune effector functions [16,17]. Thus,
it is of significant interest to understand and compare the induced subclasses in response
to vaccination with AP205-RBM.
Our results showed that vaccination with AP205-RBM enhanced the class-switching
to IgG2a and IgG1. Induction of IgG2b and IgG3 could also be detected but to a much
lesser extent (Figure 3C–E).
3.4. The Induced IgG Antibodies against RBD and Spike Protein by AP205-RBM Vaccine Are of
High Avidity
The avidity of antibodies can be defined as the binding strength through more than
one point of interaction. Avidity can be quantified as the ratio of Kd for the intrinsic affinity
over the one for functional affinity [18]. Nevertheless, avidity term can be exchanged
in a looser sense with functional affinity [19]. Modified immunoassays can be used to
determine the avidity of the induced antibodies after vaccination. This is carried out by
using 7 M Urea washes to detach low avidity antibodies. To this end, ELISA plates were
coated with RBD or Spike protein and sera from the terminal bleeding on day 49 were used
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for further analysis. After incubation with serum dilutions, half the ELISA plates were
washed using PBST + 0.05% Tween 20 while the other half was washed using 7 M Urea
in PBS + 0.05% Tween 20 as explained in the method section. The results indicate that the
induced antibodies against RBD or Spike proteins are of high avidity (Figure 4A,C). When
measuring the OD50 of RBD or Spike-specific antibodies, the small differences between
the groups washed with PBST or Urea were confirmed (Figure 4B,D), indicating the high
avidity of the induced antibodies by the vaccine candidate. To corroborate these findings,
we tested the sera of vaccinated mice in ELISA plates coated with very low concentration of
RBD (0.10 µg/mL), where we also obtained strong signal, indicating good affinity/avidity
of the induced antibodies (Figure 4E,F).
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three-fold serial serum dilution was used starting from 1:20. One representative of 2 similar experiments is shown. The
value of p < 0.05 was considered statistically significant (* p < 0.01, ** p < 0.001).
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given as reciprocal dilut on values), three-fold serial seru ere used starting from 1:20. (C) RBD-specific IgG1,
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49 measured with OD450, three-fold serial serum dilution were used starting from 1:20. (D) RBD-specific IgG1, IgG2a,
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p < 0.05 was considered statistically significant (* p < 0.01, ** p < 0.001).
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Figure 4. The induced IgG antibodies against RBD and Spike protein by AP205-RBM vaccine are of
high avidity. (A,B) RBD-specific IgG titer for the groups vaccinated with AP205 control or AP205-
RBM vaccine using sera from day 49, measured by ELISA (OD50 in B: given as reciprocal dilution
values), Plates were incubated in duplicate, after serum incubation one plate was treated with PBS
+ 0.05% Tween 20 and the other plate with 7 M Urea in PBS + 0.05% Tween 20. Three-fold serial
serum dilution was used starting from 1:20. (C,D) Spike-specific IgG titer for the groups vaccinated
with AP205 control or AP205-RBM vaccine using sera from day 49, measured by ELISA (OD50 in
D: given as reciprocal dilution values). (E,F) RBD-specific IgG titer for the groups vaccinated with
AP205 control or AP205-RBM vaccine using sera from day 49, measured by ELISA (OD50 in F: given
as reciprocal dilution values), Three-fold serial serum dilution was used starting from 1:20. One
representative of 2 similar experiments is shown. The value of p < 0.05 was considered statistically
significant (* p < 0.01, ** p < 0.001).
3.5. The AP205-RBM Vaccine Candidate Induces Antibodies Neutralizing SARS-CoV2
The best correlates of protection are virus neutralization for most viral infections and
most likely also for SARS-CoV-2. Accordingly, we performed two types of neutralization
assays, one using pseudotyped Vesicular Stomatitis Virus with SARS-CoV-2 spike, as well
as “real” SARS-CoV-2. For the pseudotyped virus neutralization assay, pseudo-types with
the S glycoprotein of SARS-CoV-2 and luciferase for quantification were used to evaluated
serum for neutralizing activity against the spike protein. Neutralization activity of the
immunized mouse sera were assessed and directly demonstrated the anti-viral neutralizing
activity of the induced antibodies (Figure 5A). For the neutralization assay with SARS-CoV-
2, we used the CPE neutralization method using 100 TCID50 of SARS-CoV-2/ABS/NL20.
Also, in this assay, the induced antibodies we were neutralizing could completely inhibit
viral replication (Figure 5B).
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Figure 5. The AP205-RBM vaccine candidate induces antibodies neutralizing SARS-CoV2. (A) Neutralization titer of the
induced antibodies using a SARS-CoV-2 pseudotyped vesicular stomatitis virus (VSV) assay. (B) eutralization titer of the
induced antibodies using CPE method and 100 TCID50 of SARS-CoV-2/ABS/NL20 virus. One representative of 2 similar
experiments is shown. The value of p < 0.05 was considered statistically significant (* p < 0.01, ** p < 0.001).
4. Discussion
Our first attempt to generate a COVID-19 vaccine was based on producing a recombi-
nant RBD in human eukaryotic cells and chemically coupling the domain to CuMVTT-VLPs,
resulting in a vaccine candidate that binds to ACE2 and induces neutralizing antibodies
in mice [20]. Chemical coupling techniques have proven efficacious for the production of
numerous vaccine candidates [21–25]. However, to facilitate GMP-compatible production
at a large-scale, genetic fusion techniques may be considered a better option. Purification
of recombinantly produced VLPs may be performed at a large scale using continuous flow,
ultracentrifugation which is currently used for producing 85% of the world’s influenza
vaccine supplies [26]. Hence, the vaccine candidate detailed in this study based on stabi-
lized AP205 VLPs, may offer advantages in terms of large-scale production compared to
the previously described one.
It has recently been shown that in contrast to most parts of the spike protein, RBD
shows minimal glycosylation as it only contains two glycosylation sites, while the RBM is
not glycosylated at all. Furthermore, the two glycosylation sites of RBD are distant from
the RBD-ACE2 interaction interphase (RBM) and do not interfere with the Spike-ACE2
receptor interaction [8]. The fact that RBM, which contains the actual ACE2 binding site, is
not glycosylated indicates that the virus cannot exploit glycan shielding to escape immune
response without attenuating its infectivity [27]. Importantly, bacterial expression systems
may therefore be suitable for productions of RBM-based vaccines, as glycosylation is not of
importance. Hence, generation of vaccines inducing antibodies against RBD and especially
against RBM in bacteria is a valuable strategy to fight the pandemic [7]. Accordingly, we
have chosen RBM as our target and fused it with AP205 stabilized by fusing two capsid
proteins into a covalent dimer. This resulted in the formation of immunogenic VLPs
displaying RBM on the surface of AP205. AP205-RBM vaccine induced a high antibody
titer against both RBD and Spike protein of SARS-CoV-2 even after one dose of the vaccine,
a response that could be further enhanced by a booster immunization 4 weeks later.
The vaccine candidate not only induced high levels of antibodies, but they were
also of high avidity. Indeed, washes with 7 M Urea removed only a relatively small
fraction of antibodies, indicating that the overall response was of high avidity. Some
recent studies have shown that antibody responses induced by SARS-CoV-2 infection are
relatively weak and of rather short duration, particularly in individuals who had no or
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only moderate symptoms [28,29]. We have proposed recently that coronaviruses employ a
structural strategy to avoid the induction of strong antibody response [30]. Other viruses
can induce optimal neutralizing long-lived antibody responses owing to their repetitive
surface of typically 60 or more rigid epitopes, spaced by 5–10 nm which are recognized as
a pathogen-associated structural pattern (PASP) (AP205 VLPs have this characteristic). In
contrast, SARS-CoV-2 consists of large particles with long spike proteins embedded in a
fluid membrane. Accordingly, recruitment of complement is poor, and stimulation of B
cells remains suboptimal. A typical VLP with a diameter of ~30 nm with epitopes spaced
by 5–10 nm is efficiently recognized by natural IgM, activates the classical complement
pathway, enhances B cell activation [31,32] and facilitates deposition of VLPs on follicular
dendritic cells, supporting the generation of germinal centers [33] and promoting the
formation of long-lived plasma cells resulting in durable antibody responses. As the
antibodies induced by the vaccine candidate were of high avidity for the RBD as well as the
whole spike protein of SARS-CoV-2, it will be interesting to reveal how this high specificity
will affect recognition of RBDs of the newly emerging mutants, such as the British (B.1.1.7),
the South African (B.1.351) or Brazilian (P.1) variant. Indeed, we have previously shown
that sera from convalescent patients essentially fail to recognize the P.1 variant [34], while
the serum from individuals immunized with Pfizer’s BNT162b2 showed 10-fold lower
recognition [35]. Thus, cross-recognition of RBDs from mutant viruses may be a critical
issue for the future.
Mouse infection with different viruses can trigger an antibody response that is often
dominated by the IgG2a subclass. IgG2a shows several better functional properties in com-
parison to other subclasses [36,37]. These properties include: binding to Fc receptors [38],
activating complement pathways [39] and mediating the process of antibody-dependent
cell-mediated cytotoxicity [40]. A prominent example are antibodies against the ectodomain
of influenza M2 protein, which potently protect mice from influenza virus if produced as
IgG2a antibodies but fail to do so if produced as IgG1 [41].
We have previously shown that RNA packaged in VLPs is responsible for efficient
isotype switch to IgG2a and this response was dependent on TLR7/8 signaling in B
cells [42]. Furthermore, bacterial RNA was found to be the most efficient type of RNA
for generation of IgG2a, rendering bacterial expression systems optimal for this type of
vaccine [43]. Hence, the E. coli-based process used here for vaccine production may not
only be highly scalable but also results in the most protective antibody responses.
IgA antibodies may be a potent weapon against SARS-CoV-2, as they are expected
to neutralize the virus locally on mucosal surfaces without enhancing inflammation via
Fc receptors. It is, therefore, interesting to note that we observed induction of strong
serum IgA responses by our vaccine candidate. We have previously shown in mice that s.c.
immunization with RNA-loaded VLPs results in a systemic IgA response, again dependent
on TLR7/8 expression in B cells [44]. This route of immunization did, however, not result in
mucosal IgA responses. It remains to be seen whether s.c. immunization with RNA-loaded
VLPs results in mucosal IgA responses in humans.
We have not directly measured induction of Th cells responses by our vaccine candi-
date, mostly because the expected effector mechanism is induction of neutralizing antibod-
ies. In addition, the size of the RBM domain of roughly 70 amino acids may be too small to
reliably induce a Th cell response in inbred mice. However, we have previously shown
that VLP-specific Th cell responses mediate isotype switch for B cells specific for antigens
displayed on the VLPs. Furthermore, the bacterial RNA packaged in VLPs, such as AP205,
drive CD8 and Th1 responses [45–47]. Thus, RNA-loaded VLPs and antigens displayed by
them induce Th cell dependent isotype-switching and Th1 responses.
Taken together, we show in this study that the bacteriophage-derived AP205 VLPs
consisting of dimerized capsid proteins may efficiently be used as a vaccine template
for insertion of RBM domain. The resultant vaccine shows high immunogenicity and
induced antibodies were neutralizing and able to block virus replication in two independent
neutralization assays.
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